Swiss Medical Weekly
VerifiedJournal
Swiss Medical Weekly, which began publication in 1871 as “Correspondenz-Blatt für Schweizer Aerzte”, is an international peer-reviewed medical journal following the Platinum Open Access model. Platinum Open Access means that the articles are published fully open access and that the journal does not charge any APCs (article-processing charges).
The "Swiss Medical Weekly" is supported by the Swiss Academy of Medical Sciences (SAMS) and the Swiss Medical Association (FMH). Source
Actions
Media Outlet details
| Scope | International, Trade/B2B |
|---|---|
| Language | English |
| Country | Switzerland |
Similarweb UVM
|
Request pricing |
Comscore UVM
|
Request pricing |
| Frequency | Weekly |
| Days Published | N/A |
| Accepts contributed content | Yes |
Recent Articles
Search ArticlesNocardia farcinica septic bursitis – a case report and scoping literature review
Skip to main navigation menu Skip to main content Skip to site footer DOI: https://doi.org/10.57187/5110 Clinical reasoning: Case report Vol. 156 No. 7 (2026) Cite this as: Swiss Med Wkly. 2026;156:5110 Published 08.07.2026 BACKGROUND: Septic bursitis is mainly caused by Staphylococcus aureus and Streptococcus spp. However, patients with immunosuppression may develop infections caused by rare pathogens.
Incidence of long COVID-related consultations in family medicine in Switzerland: a cross-sectional study within the Sentinella network
Skip to main navigation menu Skip to main content Skip to site footer DOI: https://doi.org/10.57187/4300 Original article Vol. 156 No. 7 (2026) Cite this as: Swiss Med Wkly. 2026;156:4300 Published 02.07.2026 STUDY AIMS: The initial prevalence estimates of long COVID exhibited significant heterogeneity. In Switzerland, early findings estimated a 39–53% prevalence of long COVID symptoms among adult patients who tested positive for SARS-CoV-2.
Metamizole-induced agranulocytosis: utilisation trends, pharmacovigilance signals and regulatory risk-minimisation in Switzerland
Skip to main navigation menu Skip to main content Skip to site footer DOI: https://doi.org/10.57187/5062 Original article Vol. 156 No. 6 (2026) Cite this as: Swiss Med Wkly. 2026;156:5062 Published 26.06.2026 INTRODUCTION: The therapeutic role of metamizole (dipyrone) remains controversial because of the risk of metamizole-induced agranulocytosis, a very rare, idiosyncratic, life-threatening adverse reaction.
Drug prescription before and after implementation of a CPOE system on the Paediatric Intensive Care Unit: a quality improvement study
Skip to main navigation menu Skip to main content Skip to site footer DOI: https://doi.org/10.57187/4978 Original article Vol. 156 No. 6 (2026) Cite this as: Swiss Med Wkly. 2026;156:4978 Published 18.06.2026 STUDY AIMS: Paediatric drug prescription is complex, especially in the paediatric intensive care unit (PICU), where errors may be particularly harmful due to frequent use of high-risk medications.
Female genital mutilation/cutting and risk of obstetric anal sphincter injury at delivery
DOI: https://doi.org/10.57187/4785 Original article Vol. 156 No. 6 (2026) Cite this as: Swiss Med Wkly. 2026;156:4785 Published 17.06.2026 OBJECTIVE: To assess the incidence of obstetric anal sphincter injuries in women with female genital mutilation/cutting (FGM/C) who delivered vaginally at the University Hospital in Geneva and to examine potential predictive factors for obstetric anal sphincter injuries. DESIGN: Retrospective observational study.
Microplastics in the air and potential health risks – a narrative review
DOI: https://doi.org/10.57187/4935 Review article Vol. 156 No. 6 (2026) Microplastics in the air and potential health risks – a narrative review Cite this as: Swiss Med Wkly. 2026;156:4935 Published 17.06.2026 Summary AIM: Microplastics, defined as plastic particles smaller than 5 mm and larger than 1 micrometer, along with nanoplastics (in the 1–1000 nm range), are ubiquitous environmental contaminants originating from both primary production and secondary fragmentation.
Trends in health- and lifestyle-related aspects in women of childbearing age: analysis of Swiss Health Survey data between 1992 and 2022
DOI: https://doi.org/10.57187/5069 Original article Vol. 156 No. 6 (2026) Trends in health- and lifestyle-related aspects in women of childbearing age: analysis of Swiss Health Survey data between 1992 and 2022 Cite this as: Swiss Med Wkly. 2026;156:5069 Published 17.06.2026 Summary OBJECTIVE: Changes in societal lifestyle trends can influence women’s health and alter their risk profile. In women of childbearing age, this can affect their pregnancy outcomes and the health of their future children.
General consent: a mixed-method and patient-inclusive approach to explore and optimise information strategies
Skip to main navigation menu Skip to main content Skip to site footer DOI: https://doi.org/10.57187/4812 Original article Vol. 156 No. 6 (2026) Cite this as: Swiss Med Wkly. 2026;156:4812 Published 11.06.2026 STUDY AIMS: Little is known about the factors influencing patients’ response and decision rates to requests for general consent, designed to cover the use of health-related personal data and biological samples, in tertiary university hospitals.
The evolution of kidney surgery for renal masses in Switzerland – a retrospective analysis
Skip to main navigation menu Skip to main content Skip to site footer DOI: https://doi.org/10.57187/4878 Original article Vol. 156 No. 6 (2026) Cite this as: Swiss Med Wkly. 2026;156:4878 Published 03.06.2026 INTRODUCTION: According to international guidelines, partial nephrectomy is recommended as the standard of care in patients with cT1 kidney tumours, as well as in those with cT2, whenever technically feasible.
Expanding hepatocellular carcinoma surveillance strategies in high-risk patients in Switzerland: a cost-effectiveness analysis
Skip to main navigation menu Skip to main content Skip to site footer DOI: https://doi.org/10.57187/4469 Original article Vol. 156 No. 5 (2026) Cite this as: Swiss Med Wkly. 2026;156:4469 Published 28.05.2026 BACKGROUND: European and Swiss guidelines recommend hepatocellular carcinoma surveillance of high-risk patients every 6 months using ultrasound (US), with/without α-fetoprotein (AFP). Other surveillance strategies are available, but evidence of their comparative cost-effectiveness is lacking.